Overview: In this presentation, learn about the latest innovations to enable absolute molecular quantification. The automation compatible QuantStudio Absolute Q Digital PCR system will be highlighted, showcasing high throughput consistent data without the need for standard curves.
Clarence Lee, Ph.D.
Sr. Product Manager, Digital PCR, Thermo Fisher Scientific
Overview: Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies, such as digital PCR (dPCR) and next-generation sequencing (NGS), have enabled researchers to more comprehensively detect and study cancer-related mutations, even when they are very rare.
With this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management.
|Dr. Cristina Bilbao|
Senior Researcher in Molecular Biology, working in Hematology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria
|Dr. Paul Hung|
Senior Director and General Manager of Digital PCR, Thermo Fisher Scientific
|Dr. K J Kao|
Head of the Department of Molecular Medicine and Research, Koo Foundation Sun Yat-Sen Cancer Center
|Dr. Cloud Paweletz|
Head of Research at the Belfer Center for Applied Cancer Science, Dana Faber Cancer Institute (DFCI)
|Dr. Luca Quagliata|
Vice President and Global Head of Medical Affairs for the Clinical Sequencing Oncology Division, Thermo Fisher Scientific
Overview: This on-demand webinar will cover dPCR basics and the differences between dPCR and qPCR and provide an overview of the QuantStudio Absolute Q dPCR System.
Abstract: Programmable RNA base editors are excellent tools to modify RNA transcripts at precise locations or designated hotspots. Post editing, it is critical to provide precise and accurate quantification for the successful editing events to determine the activity and efficiency of the RNA base editor enzymes used. Digital PCR is a specialized tool which facilitates accurate absolute quantification of nucleic acid targets. By splitting a bulk PCR reaction across many micro-reactions, robust and reproducible absolute quantification is possible without the need for a standard curve. APOBEC3A, CRISPR programmable RNA base editors, or other enzymes can edit RNA transcripts at specific locations or hotspots. Precise quantification of these RNA-editing events is crucial to determine the activity and efficiency of these enzymes in cells. The Buisson lab has developed a quick method to quantify RNA-editing activity using digital PCR, a sensitive and quantitative technique to detect rare RNA mutations induced by APOBEC3A by digitizing a bulk PCR reactions. This assay allows rapid absolute quantification of RNA editing events caused by APOBEC3A in cell lines or patient samples.
Dr. Buisson is an assistant professor at the University of California Irvine. The Buisson laboratory studies mechanisms used by cancer cells to exploit APOBEC3A and increase the level of mutations in their genomes to promote cancer progression. The long-term goal of Dr. Buisson is to develop therapeutic strategies to suppress the accumulation of mutations in tumors induced by APOBEC3A to prevent tumor heterogeneity and drug resistance.
Abstract: Digital PCR is a specialized tool for nucleic acid quantification, which has applications in many research areas including those in microbiology and virology research. Leveraging optical multiplexing, multiple targets expected within a single sample can be tested in a single digital PCR reaction, providing absolute quantification without the need for a reference or standard curve.
In this webinar, invited speaker Dr. Joan L. Slonczewski of Kenyon College describes their ongoing research, which leverages digital PCR.
Dr. Slonczewski is Professor of Biology at Kenyon College, where she teaches microbiology and virology. She graduated from Bryn Mawr College (A.B.) and her PhD is from Yale University, Department of Molecular Biophysics and Biochemistry. Her research funded by NSF addresses the evolution of bacterial stress response and the reversal of bacterial drug resistance. In 2021 she implemented wastewater monitoring for SARS-CoV-2 on behalf of a village community in rural Ohio. The method involves viral RNA detection using the Applied Biosystems QuantStudio Absolute Q digital PCR system.
In this session, Robert Lin, PhD, Senior Product Manager of Digital PCR at Thermo Fisher Scientific, will explore the benefits of each technology and how, used together, each strength can be leveraged to tell a more compelling and complete story at the molecular level.
An interactive Q&A session with Thermo Fisher Scientific Executives on the future of digital PCR and launch of the QuantStudio Absolute Q digital PCR system.
For Research Use Only. Not for use in diagnostic procedures.